Compare Neurocrine Biosciences Inc (NBIX) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Peloton Interactive Inc — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Peloton Interactive Inc trades at $4.92 (market cap $2.16B). The key difference: Neurocrine Biosciences Inc is far larger — about 6.6× Peloton Interactive Inc's market cap, and Peloton Interactive Inc is more actively traded (11,369,487 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Peloton Interactive Inc for 37 Days on average.
| NBIX | PTON | |
|---|---|---|
Market Cap | $14.36B | $2.16B |
Volume | 1,237,180 | 11,369,487 |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $7.86 |
52-Week Low | $123.10 | $3.71 |
Typical Hold Time | 23 Days | 37 Days |
Enterprise Value | $14.37B | $2.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Peloton (PTON) trades at $4.85, down 0.41% on the day, amid a bearish technical signal and mixed earnings history. The company reported its first full-year net profit in 2026 with a 2.58% net income margin, yet revenue has declined from $3.6B in 2022 to $2.4B in 2026. Positive cash flow trends and a new product launch, including a foldable treadmill, aim to revive growth, but negative shareholder equity and high debt levels persist as concerns.
The outlook hinges on execution of the turnaround strategy; upside exists if new products boost subscriptions, but risks include persistent subscriber declines and high leverage. Analyst consensus is a Buy with a $8.00 price target, suggesting significant potential appreciation from current levels if operational improvements continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
